Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Pharma (IGC) over the last 12 years, with Q3 2025 value amounting to -$0.02.

  • Pharma's EPS (Weighted Average and Diluted) changed 0.0% to -$0.02 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.07, marking a year-over-year increase of 6111.11%. This contributed to the annual value of -$0.09 for FY2025, which is 5769.81% up from last year.
  • As of Q3 2025, Pharma's EPS (Weighted Average and Diluted) stood at -$0.02, which was down 0.0% from -$0.02 recorded in Q2 2025.
  • Pharma's EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.02 during Q1 2025, with a 5-year trough of -$0.09 in Q4 2023.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$0.03, with a median of -$0.02 in 2024.
  • As far as peak fluctuations go, Pharma's EPS (Weighted Average and Diluted) skyrocketed by 7777.78% in 2024, and later changed by 0.0% in 2025.
  • Over the past 3 years, Pharma's EPS (Weighted Average and Diluted) (Quarter) stood at -$0.09 in 2023, then skyrocketed by 77.78% to -$0.02 in 2024, then changed by 0.0% to -$0.02 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$0.02 for Q3 2025, versus -$0.02 for Q2 2025 and -$0.02 for Q1 2025.